|
Listen to this article
 |
The Genesis RMN system is part of the cardiac program at the University of Kansas Health System. | Source: Stereotaxis
Stereotaxis Inc. last week announced that physicians at the University of Kansas Health System successfully treated the first patients with its Genesis system.
The first use of the Genesis robotic magnetic navigation (RMN) system comes as part of a robotic heart program at the health system. Genesis delivers the benefits of robotic precision and safety to cardiac ablation to treat arrhythmias, said the St. Louis, Mo.-based company.
“For years, advanced robot technology has been instrumental in our ability to deliver superior care to our patients, allowing us to navigate complex cardiac procedures with improved accuracy and safety,” said Dr. Seth Sheldon, cardiac electrophysiologist at the health system. “The robotic precision and stability offered by the Genesis System allows us to deliver precise, personalized treatments to our patients, ultimately improving outcomes and quality of life.”
Genesis uses smaller magnets that rotate along their center of mass, allowing for responsiveness to physician control. The smaller system can improve the patient experience, provide greater patient access, and increase lab space, said Stereotaxis.
Flexible, rugged robotic arms hold the agents to increase the potential range of motion and allow for wider X-ray angulation.
More about Stereotaxis
A hospital in Kentucky performed the first procedures with the Genesis surgical robot late last year. Stereotaxis also has an ongoing collaboration with Abbott, which had milestone developments last fall.
“We are proud to continue our partnership with the health system to deliver exceptional cardiac care to patients in Kansas City,” said David Fischel, chairman and CEO of Stereotaxis. “We look forward to continuing to support their successful and impactful robotic heart-rhythm care program.”
In August, Stereotaxis submitted its next-generation GenesisX system to the U.S. Food and Drug Administration (FDA) following its receipt of the CE mark in Europe. The company said its technology has been used to treat over 150,000 patients around the world.
MassDevice listed Stereotaxis as one of the 10 surgical robotics companies worth following in 2024.
Editor’s note: This article was syndicated from The Robot Report sibling site MassDevice.
Tell Us What You Think!